MX2022001158A - Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. - Google Patents

Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.

Info

Publication number
MX2022001158A
MX2022001158A MX2022001158A MX2022001158A MX2022001158A MX 2022001158 A MX2022001158 A MX 2022001158A MX 2022001158 A MX2022001158 A MX 2022001158A MX 2022001158 A MX2022001158 A MX 2022001158A MX 2022001158 A MX2022001158 A MX 2022001158A
Authority
MX
Mexico
Prior art keywords
inhibitors
dna
tumor therapy
dual atm
atm
Prior art date
Application number
MX2022001158A
Other languages
English (en)
Inventor
Jianmin Fu
Guosheng Wu
Aijun Lu
Yaode Wang
Yue Sun
Shuang Zhang
Tona Gilmer
Michael Kastan
David Kirsch
Robert A Goodnow
Original Assignee
Xrad Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201910695148.4A external-priority patent/CN112300159A/zh
Application filed by Xrad Therapeutics Inc filed Critical Xrad Therapeutics Inc
Publication of MX2022001158A publication Critical patent/MX2022001158A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan en la presente compuestos de la Fórmula (I): (ver Fórmula), y sales farmacéuticamente aceptables de estos, donde los sustituyentes son los que se describieron en la presente. Estos compuestos, y sus composiciones farmacéuticas, pueden ser útiles para el tratamiento de enfermedades oncológicas.
MX2022001158A 2019-07-30 2020-07-30 Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. MX2022001158A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910695148.4A CN112300159A (zh) 2019-07-30 2019-07-30 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
US201962883325P 2019-08-06 2019-08-06
PCT/US2020/044322 WO2021022078A1 (en) 2019-07-30 2020-07-30 Dual atm and dna-pk inhibitors for use in anti-tumor therapy

Publications (1)

Publication Number Publication Date
MX2022001158A true MX2022001158A (es) 2022-02-22

Family

ID=74229877

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001158A MX2022001158A (es) 2019-07-30 2020-07-30 Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.

Country Status (11)

Country Link
US (1) US20220142995A1 (es)
EP (1) EP4003345A4 (es)
JP (1) JP2022542285A (es)
KR (1) KR20220047290A (es)
CN (1) CN114258301A (es)
AU (1) AU2020322026A1 (es)
BR (1) BR112022001067A2 (es)
IL (1) IL289542A (es)
MX (1) MX2022001158A (es)
WO (1) WO2021022078A1 (es)
ZA (1) ZA202201499B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310848A (en) * 2021-08-17 2024-04-01 Telix Pharmaceuticals Innovations Pty Ltd Combined radiotherapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015192761A1 (zh) * 2014-06-17 2015-12-23 辰欣药业股份有限公司 作为mTOR/PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
EP3560924B1 (de) * 2015-04-02 2021-03-31 Merck Patent GmbH Imidazolonylchinoline und deren verwendung als atm-kinase-inhibitoren
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
MA44674B1 (fr) * 2016-04-15 2020-06-30 Abbvie Inc Inhibiteurs de bromodomaine
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy

Also Published As

Publication number Publication date
JP2022542285A (ja) 2022-09-30
WO2021022078A1 (en) 2021-02-04
US20220142995A1 (en) 2022-05-12
AU2020322026A1 (en) 2022-02-03
KR20220047290A (ko) 2022-04-15
CN114258301A (zh) 2022-03-29
EP4003345A1 (en) 2022-06-01
BR112022001067A2 (pt) 2022-05-24
IL289542A (en) 2022-03-01
ZA202201499B (en) 2023-11-29
EP4003345A4 (en) 2023-07-26

Similar Documents

Publication Publication Date Title
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
SA520420033B1 (ar) مركبات صيدلية
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2023007192A (es) Inhibidores de prmt5.
EA202092320A1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
MY183036A (en) Amino-triazolopyridine compounds and their use in treating cancer
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
MX2020001719A (es) Inhibidores macrocíclicos de mcl-1 y metodos de uso.
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
SA521421098B1 (ar) -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
NZ777925A (en) Deoxy- cytidine or uridine derivatives for use in cancer therapies
MX2021012499A (es) Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.
WO2016112304A8 (en) Furoquinolinediones as inhibitors of tdp2
MX2022007474A (es) Compuestos macrociclicos.
NZ770629A (en) Pyridopyrimidinone derivatives for use as axl inhibitors